Recombinant Cynomolgus CD200R1 His-tag Protein, CF

When Recombinant Cynomolgus Monkey CD200 R1 (Catalog # 10055-CD) is coated at 0.5 μg/mL, 100 μL/well, Recombinant Human CD200 Fc Chimera (Catalog # 2724-CD) binds with an ED50 of 0.02‑0.12 μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey CD200 R1 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 60-67 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus CD200R1 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey CD200 R1 is coated at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Human CD200 Fc Chimera (Catalog # 2724-CD) that produces 50% optimal binding response is 0.02‑0.12 μg/mL
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey CD200R1 protein
  Ala27-Leu267, with a C-terminal 6-His tag
• Accession #: XP_005548208
• N-terminal Sequence: Ala27
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 28 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-67 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 1 mg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus CD200R1 His-tag Protein, CF

• CD200 R1
• CD200 receptor 1
• CD200R1
• CD200RMOX2Rcell surface glycoprotein CD200 receptor 1
• Cell surface glycoprotein OX2 receptor 1
• cell surface glycoprotein receptor CD200
• CRTR2
• HCRTR2
• MOX2 receptor
• MOX2R
• OX2RCD200 cell surface glycoprotein receptor

Background

CD200 R1, also known as OX-2 receptor, is a 90 kDa transmembrane protein in the immunoglobulin superfamily and is important in the regulation of myeloid cell activity (1-3). The cynomolgus CD200 R1 cDNA encodes a 241 amino acid (aa) extracellular domain (ECD) and 61 aa cytoplasmic tail. The ECD is composed of one Ig-like V‑type domain and one Ig-like C2-type domain (4). Within the ECD, cynomolgus CD200 R1 shares 91%, 54%, and 57% aa sequence identity with human, mouse, and rat CD200 R1, respectively. Alternate splicing of the human CD200 R1 mRNA generates four isoforms, two of which are truncated in the Ig-C2 domain and are likely secreted (5). CD200 R1 expression is restricted primarily to mast cells, basophils, macrophages, and dendritic cells (6-8), while its ligand, CD200, is widely distributed (9). Disruption of this receptor-ligand system by knockout of the CD200 gene in mice leads to increased macrophage number and activation and predisposition to autoimmune disorders (10). Association of CD200 with CD200 R1 takes place between their respective N-terminal Ig-like domains (11). CD200 R1 propagates inhibitory signals despite lacking a cytoplasmic ITIM (immunoreceptor tyrosine-based inhibitory motif) (7, 8, 12, 13). CD200R1 signaling inhibits the expression of proinflammatory molecules including TNFs, IFNs, and inducible nitric oxide synthase in response to selected stimuli, which implicate that CD200/CD200R1 inhibitory signaling pathway plays a prominent role in limiting inflammation in a wide range of inflammatory diseases (14). Furthermore, the CD200/CD200R inhibitory signaling constitutes one of the most suitable endogenous immunoregulatory molecule candidate to restore the immune suppressive status of the CNS altered in chronic neuroinflammatory situations (15).

1. Rosenblum, M.D. et al. (2006) J. Dermatol. Sci. 41:165.
2. Gorczynski, R.M. (2005) Curr. Opin. Invest. Drugs 6:483.
3. Barclay, A.N. et al. (2002) Trends Immunol. 23:285.
4. Wright, G.J. et al. (2003) J. Immunol. 171:3034.
5. Vieites, J.M. et al. (2003) Gene. Jun. 5; 311:99.
6. Shiratori, I. et al. (2005) J. Immunol. 175:4441.
7. Cherwinski, H.M. et al. (2005) J. Immunol. 174:1348.
8. Fallarino, F. et al. (2004) J. Immunol. 173:3748.
9. Wright, G.J. et al. (2001) Immunology 102:173.
10. Hoek, R.M. et al. (2000) Science 290:1768.
11. Hatherley, D. and A.N. Barclay (2004) Eur. J. Immunol. 34:1688.
12. Jenmalm, M.C. et al. (2006) J. Immunol. 176:191.
13. Zhang, S. et al. (2004) J. Immunol. 173:6786.
14. Vaine, C.A. et al. (2014) Adv Immunol.121: 191.
15. Hernangómez, M. et al. (2014) Curr Pharm Des. 20:4707.

Bioinformatics

• Uniprot:
  • XP_005548208()